I found the company information on this it's a company called airmid and from the website I was able to find proof it has gone on to human testing. I was also able to find the email address for Dr. Chandy who gave this presentation I have emailed him to inquire how it is coming along.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Target Portfolio >> Proof-of-concept AIRMID Technology
In Humans:

* Disease-associated autoreactive T cells are effector-memory T cells with elevated Kv1.3 expression.
* PAP-1 and ShK-186 suppress effector memory T cell- proliferation and cytokine production without impacting naïve and central memory T cells.

In Animals:

* ShK-186 and PAP-1 ameliorate disease in many models of autoimmune disease
* Multiple sclerosis
o Adoptive experimental autoimmune encephalomyelitis
chronic relapsing-remitting EAE
o Rheumatoid arthritis pristane-induced arthritis
* Type-1 diabetes mellitus
o experimental autoimmune diabetes mellitu
* Contact dermatitis (and psoriasis)
o Acute allergic
o Contact dermatitis
* Other effector memory-mediated T cell
o Responses Delayed type hypersensit

Independent Confirmation:

Merck: Kv1.3 blockers suppress effector memory T cell-mediated delayed type hypersensitivity in animals. Harvard Dental School: Kv1.3 blocker ameliorated effector memory T cell-mediated experimental bone resorption associated with periodontitis. University of Marseille: Kv1.3 blocker ameliorated effector memory T cell-mediated adoptive experimental autoimmune encephalomyelitis and delayed-type hypersensitivity.



website: http://www.airmid.com/index.html